Sarcopenia

Decoding Sarcopenia: Advances in Research and Management: Dive into the evolving landscape of sarcopenia research. From cutting-edge studies on its impact on cancer patients to innovative management strategies, gain insights into combating this muscle-wasting condition.

Sarcopenia and body composition abnormalities in chronic pancreatitis: Pathophysiology, assessment, and clinical impact.

Chronic pancreatitis is a progressive inflammatory disease associated with substantial nutritional and metabolic consequences. Beyond classical malnutrition, patients frequently develop alterations in body composition, particularly sarcopenia, which are increasingly recognised as clinically relevant but remain inconsistently assessed. The reported prevalence...

🗓️ 2026-06-12
📰 Publication: Clinical Nutrition
Read MoreSarcopenia and body composition abnormalities in chronic pancreatitis: Pathophysiology, assessment, and clinical impact.

Association of Airway Mucus Plugs and Physical Activity, Exercise Tolerance, Sarcopenia, and Frailty in Patients With COPD and Pre-COPD.

BACKGROUND AND OBJECTIVE

Airway mucus plugs on computed tomography (CT) are an imaging biomarker of chronic obstructive pulmonary disease (COPD) associated with airflow limitation, respiratory symptoms, and poor prognosis. However, clinical phenotypes relevant to mucus plugs, including sarcopenia and frailty, are...

🗓️ 2026-06-12
📰 Publication: Respirology
Read MoreAssociation of Airway Mucus Plugs and Physical Activity, Exercise Tolerance, Sarcopenia, and Frailty in Patients With COPD and Pre-COPD.

Increased epicardial adipose tissue area and radiodensity in sarcopenic obesity.

BACKGROUND

Sarcopenic obesity (SO) confers substantially greater cardiometabolic risk than either sarcopenia or obesity alone, but the tissue-level structural alterations underlying this risk remain unclear. Epicardial adipose tissue (EAT) characteristics, including both area and radiodensity, may provide clinically relevant insight into...

🗓️ 2026-06-11
📰 Publication: Cardiovascular Diabetology
Read MoreIncreased epicardial adipose tissue area and radiodensity in sarcopenic obesity.

Validation and application of automated CT analysis to musculoskeletal profiling in MVC occupants.

OBJECTIVE

Bone mineral density (BMD) and muscle health influence an occupant's tolerance to motor vehicle crash (MVC), and these musculoskeletal factors can be used to design more effective countermeasures. CT imaging routinely acquired during trauma evaluation can be leveraged to obtain...

🗓️ 2026-06-11
📰 Publication: Traffic Injury Prevention
Read MoreValidation and application of automated CT analysis to musculoskeletal profiling in MVC occupants.

Diagnostic Utility of Muscle Ultrasound for Sarcopenia in Prader-Willi Syndrome: A Cross-Sectional Study.

BACKGROUND

Prader-Willi syndrome (PWS) is characterized by sarcopenic obesity; however, validated screening tools for muscle mass in clinical settings are lacking. This study aimed to evaluate the diagnostic utility of muscle ultrasound (US) for detecting low muscle mass in individuals with...

🗓️ 2026-06-09
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreDiagnostic Utility of Muscle Ultrasound for Sarcopenia in Prader-Willi Syndrome: A Cross-Sectional Study.

Sarcopenia Predicts Mortality and Hepatic Encephalopathy After TIPS in Older Adults With Cirrhosis and Improves Prognostic Scores.

BACKGROUND AND AIMS

The role of transjugular intrahepatic portosystemic shunt (TIPS) in older adults remains controversial because of limited risk-stratification tools. We aimed to assess whether sarcopenia and myosteatosis are independently associated with post-TIPS mortality and overt hepatic encephalopathy (OHE) in...

🗓️ 2026-06-08
📰 Publication: Liver International
Read MoreSarcopenia Predicts Mortality and Hepatic Encephalopathy After TIPS in Older Adults With Cirrhosis and Improves Prognostic Scores.

Sarcopenia in the Metropolitan Region of Chile: Cross-Sectional Findings from the Chilean National Health Survey 2016-2017.

AIM

To investigate sarcopenia in Chile, including its prevalence and association with sociodemographic and lifestyle factors.

METHODS

232 participants from the Metropolitan Region, representing 1,037,790 older adults, were included in this cross-sectional analysis. Sarcopenia was defined using the European Working Group on Sarcopenia...

🗓️ 2026-06-08
📰 Publication: Revista Medica De Chile
Read MoreSarcopenia in the Metropolitan Region of Chile: Cross-Sectional Findings from the Chilean National Health Survey 2016-2017.

Combined GLIM-defined malnutrition and sarcopenia and the risk of 2-year mortality in adults with heart failure: A FRAGILE-HF study post hoc analysis.

BACKGROUND

Malnutrition is common in older patients with heart failure and predicts poor outcomes. However, the prognostic value of assessing muscle function and fat stores alongside GLIM remains unclear. We therefore tested whether assessing handgrip strength and fat mass index alongside...

🗓️ 2026-06-03
📰 Publication: Journal Of Parenteral And Enteral Nutrition
Read MoreCombined GLIM-defined malnutrition and sarcopenia and the risk of 2-year mortality in adults with heart failure: A FRAGILE-HF study post hoc analysis.

Restoration of circadian rhythm as novel targets against sarcopenia.

Sarcopenia, characterized by the age-related decline in skeletal muscle mass, strength, and function, is associated with high healthcare costs and significant health risks, including falls, fractures, functional decline, and mortality. Despite its prevalence and extensive research, there are currently no...

🗓️ 2026-05-31
📰 Publication: Chinese Medical Journal
Read MoreRestoration of circadian rhythm as novel targets against sarcopenia.

Cluster Randomized Trial of Reablement Strategies Targeting Sarcopenia (ReStart-S) in Long-Term Care Settings.

BACKGROUND

Sarcopenia prevalence is high in long-term care settings (LTCS), yet existing guidelines often overlook this population. The Reablement Strategies targeting Sarcopenia (ReStart-S) program was developed to address this gap. This study evaluated its effects on muscle outcomes, physical performance, quality...

🗓️ 2026-05-31
📰 Publication: Journals Of Gerontology Series A-Biological Sciences And Medical Sciences
Read MoreCluster Randomized Trial of Reablement Strategies Targeting Sarcopenia (ReStart-S) in Long-Term Care Settings.

Artificial intelligence analysis of temporalis muscle thickness for monitoring sarcopenia and clinical outcomes in individuals with paediatric brain tumours: a retrospective cohort study.

BACKGROUND

People with and who have survived paediatric brain tumour (PBT) have a poor quality of life due to physiological frailty, a primary component of which is sarcopenia (ie, low lean muscle mass) and the associated condition, sarcopenic overweight. MRI-based temporalis...

🗓️ 2026-05-28
Read MoreArtificial intelligence analysis of temporalis muscle thickness for monitoring sarcopenia and clinical outcomes in individuals with paediatric brain tumours: a retrospective cohort study.

Sarcopenia in Diabetes: A proposal on integrating muscle assessment and nutritional intervention in people living with diabetes.

Sarcopenia is a progressive muscle disease characterized by loss of skeletal muscle mass and strength, commonly associated with ageing and chronic diseases. Type 2 diabetes mellitus (T2DM) accelerates its development through insulin resistance, chronic inflammation, oxidative stress, and hyperglycaemia. Sarcopenia...

🗓️ 2026-05-27
📰 Publication: Diabetes Research And Clinical Practice
Read MoreSarcopenia in Diabetes: A proposal on integrating muscle assessment and nutritional intervention in people living with diabetes.

Exploring the role of parathyroid hormone in sarcopenia: A review.

PURPOSE OF REVIEW

Sarcopenia is a progressive, multifactorial geriatric syndrome linked to increased risk of falls, fractures, disability, frailty, and all-cause mortality. The pathophysiology of this complex syndrome remains unclear. Emerging evidence suggests that chronically elevated parathyroid hormone (PTH) concentration may...

🗓️ 2026-05-27
Read MoreExploring the role of parathyroid hormone in sarcopenia: A review.

Circulating biomarkers in older adults with and without sarcopenia: a systematic review and meta-analysis.

BACKGROUND

Sarcopenia, the age-related loss of muscle mass and strength, poses a significant health and economic burden. This systematic review and meta-analysis evaluates circulating biomarkers (activin A, follistatin, growth differentiation factor (GDF-15), myostatin, growth hormone, insulin growth factor-1 (IGF-1), free and...

🗓️ 2026-05-27
📰 Publication: Journals Of Gerontology Series A-Biological Sciences And Medical Sciences
Read MoreCirculating biomarkers in older adults with and without sarcopenia: a systematic review and meta-analysis.

The Gut-Muscle Axis in Sarcopenia: Mechanisms, Evidence Gaps and Translational Challenges.

Sarcopenia is an age-related skeletal muscle disorder characterized by reduced muscle mass, strength, and physical performance, as well as increased risk of disability, hospitalization, and mortality. Emerging evidence suggests that gut microbiota alterations may contribute to muscle decline via a...

🗓️ 2026-05-27
Read MoreThe Gut-Muscle Axis in Sarcopenia: Mechanisms, Evidence Gaps and Translational Challenges.

SARCOPENIA DEFINITION

Sarcopenia is a condition which focuses on muscle loss. Loss of muscle mass and function, especially muscle strength and gait speed, associated with aging occurs in sarcopenia. Sarcopenia, cachexia, and malnutrition are considered as the main causes of muscle wasting and affect millions of elderly people and patients. Moreover, muscle atrophy can develop independently from diseases and age through disuse of the muscles. For a better classification and common language in medical science for ‘muscle wasting disease’ there is a proposal to combine the concepts of muscle wasting, sarcopenia, frailty, and cachexia by disease aetiology and disease progression. Patients with muscle atrophy show decreased muscle strength and therefore reduced quality of life, which is caused by a lower activity and increased exercise intolerance.

Despite a large number of studies, the understanding of the development of muscle wasting and the involved pathways remains very limited and more research is needed. Although many researchers and pharmaceutical companies have tried to find therapies for muscle atrophy, including cachexia and sarcopenia, no solution has been established until now.

REFERENCES

Rosenberg IH. Sarcopenia: origins and clinical relevance. Clin Geriatr Med 2011;27:337–339.

Anker SD, Coats AJ, Morley JE, Rosano G, Bernabei R, von Haehling S, Kalantar-Zadeh K. Muscle wasting disease: a proposal for a new disease classification. J Cachexia Sarcopenia Muscle 2014;5:1–3

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!